We feel now is a pretty good time to analyse Prothena Corporation plc's (NASDAQ:PRTA) business as it appears the company may be on the cusp of a considerable accomplishment. Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. On 31 December 2025, the US$501m market-cap company posted a loss of US$244m for its most recent financial year. The most pressing concern for investors is Prothena's path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts’ expectations for the company.
According to the 5 industry analysts covering Prothena, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2027, before generating positive profits of US$1.4m in 2028. Therefore, the company is expected to breakeven roughly 2 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 80%, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
We're not going to go through company-specific developments for Prothena given that this is a high-level summary, but, bear in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
View our latest analysis for Prothena
One thing we’d like to point out is that Prothena has no debt on its balance sheet, which is rare for a loss-making biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
Next Steps:
There are too many aspects of Prothena to cover in one brief article, but the key fundamentals for the company can all be found in one place – Prothena's company page on Simply Wall St. We've also compiled a list of relevant factors you should further examine:
- Valuation: What is Prothena worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Prothena is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Prothena’s board and the CEO’s background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.